Drug Profile
Research programme: IPL42 series - Inflazyme
Alternative Names: IPL42 series; PDE 4 inhibitors - Inflazyme; Phosphodiesterase IV inhibitors - InflazymeLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Respiratory tract disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in Canada
- 01 Jun 2007 Preclinical trials in Inflammation in Canada (unspecified route)